Citation

Mann JJ, Emslie G, Baldessarini RJ, Beardslee W, Fawcett JA, Goodwin FK, Leon AC, Meltzer HY, Ryan ND, Shaffer D, Wagner KD. Neuropsychopharmacology 2005; 31(3): 473–492.

Affiliation

Columbia University/New York State Psychiatric Institute, New York, NY, USA.

Copyright

(Copyright © 2005, Nature Publishing Group)

DOI

10.1038/sj.npp.1300958

PMID

16319919

Abstract

This Task Force report by the American College of Neuropsychopharmacology evaluates the safety and efficacy of selective serotonin reuptake inhibitor (SSRIs) antidepressants for depressed youth under 18 years. The report was undertaken after regulatory agencies in the United States and United Kingdom raised concerns in 2003 about the possibility that treatment of depression in children and adolescents with SSRIs may increase the risk of suicidal thinking or suicide attempts.